Case report: chemotherapy in conjunction with blood–brain barrier disruption for a patient with germ cell tumor with multiple brain metastases
Knuutinen, Oula; Kuitunen, Hanne; Alahuhta, Seppo; Isokangas, Juha-Matti; Sonkajärvi, Eila; Turpeenniemi-Hujanen, Taina; Kuittinen, Outi (2018-05-26)
Knuutinen, O., Kuitunen, H., Alahuhta, S., Isokangas, J.-M., Sonkajärvi, E., Turpeenniemi-Hujanen, T., & Kuittinen, O. (2018). Case Report: Chemotherapy in Conjunction With Blood–Brain Barrier Disruption for a Patient With Germ Cell Tumor With Multiple Brain Metastases. Clinical Genitourinary Cancer, 16(5), e993–e996. https://doi.org/10.1016/j.clgc.2018.05.005
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http:/creativecommons.org/licenses/by-nc-nd/4.0/
https://creativecommons.org/licenses/by-nc-nd/4.0/
https://urn.fi/URN:NBN:fi-fe2019122049243
Tiivistelmä
Clinical practice points
Testicular cancer with brain metastases is related to poor prognosis because the penetration of chemotherapeutic agents is decreased by the blood–brain barrier.
The standard treatment of brain metastases—whole brain radiation therapy combined with chemotherapy—is related to a limited increase in survival and considerable deleterious cognitive effects.
The blood–brain barrier can be transiently disrupted using hyperosmolar intra-arterial mannitol injection. When combined with intra-arterial chemotherapy, therapeutic intratumoral concentrations can be attained.
In experienced centers, blood–brain barrier disruption therapy is relatively safe with a low incidence of catheter-related complications.
Blood–brain barrier disruption therapy is a promising treatment modality for brain metastases as an alternative to whole brain radiation therapy.
Kokoelmat
- Avoin saatavuus [31657]